Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

legal action

- PMLiVE

Google and J&J team up for robotic surgery

Two firms looking to revolutionise medical technology

- PMLiVE

Imbruvica shines in combination trial

Showed significant increase in progression-free survival

- PMLiVE

J&J sells Cordis unit to Cardinal Health for $1.94bn

Marks J&J’s exit from the cardiovascular stent market

- PMLiVE

Complaints about UK medical advertising drop

And this year the MHRA will be vetting adverts to promote a ‘right first time’ approach

- PMLiVE

J&J gets quicker review for schizophrenia depot in US

Could be ready to market by the middle of this year

- PMLiVE

Biosimilar Remicade reaches market in Japan and India

Nippon Kayaku’s version of arthritis drug was approved in July

- PMLiVE

Olysio drives J&J pharma sales

But hepatitis C drug set to face serious competition from Gilead Sciences

- PMLiVE

Pharma spent $342m on journal advertising in first half of 2014

J&J led spending and Invokana was most advertised brand

- PMLiVE

J&J brings its Care4today mobile adherence programme to the UK

Launches the mobile app in its first market outside the US

- PMLiVE

Double win for J&J’s schizophrenia franchise

Pharma company wins appeal against $1.2bn fine and Risperdal follow-up proves itself in trial

- PMLiVE

J&J’s Care4Today brand joins Twitter

Firm's Janssen Healthcare Innovation unit also makes its debut on the social network

- PMLiVE

J&J sells diagnostics unit to private equity firm

Ortho-Clinical Diagnostics acquired by the Carlyle Group

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links